The ImmPort study (SDY1641) investigated the roles of renin-angiotensin system (RAS) inhibitors, including angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers, in treating COVID-19 patients with hypertension [26]. Here, ACE is linked to hypertensive disorder.